Markers of bone metabolism in prostate cancer

Cancer Treatment Reviews

Volumn 32, Issue SUPPL. 1, 2006, Pages 23-26

  Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alkaline phosphatase; BAP; Bone markers; Metastatic prostate cancer; NTX; Skeletal complications; TALP

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GONADORELIN AGONIST; OSTEOPROTEGERIN; PROCOLLAGEN; PROSTATE SPECIFIC ANTIGEN; SIALOPROTEIN; ZOLEDRONIC ACID;

ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE SCINTISCANNING; CANCER MORTALITY; CANCER SURVIVAL; CELL ACTIVITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL RESEARCH; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; OSTEOCLAST; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646235166     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(06)80006-X     Document Type: Article

References (36)

1. Michaelson M., and Smith M. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23 (2005) 8219-8224
2. Garnero P., Buchs N., Zekri J., et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 (2000) 858-864
3. Galasko C. The anatomy and pathways of skeletal metastasis. In: Weiss L., and Gilbert H. (Eds). Bone Metastasis (1981), Hall, Boston, MA 49-63
4. Boyce B., Yoneda T., and Guise T. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6 (1999) 333-347
5. Saad F., Gleason D., Murray R., et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
6. Gleave M., Hsieh J., von Eschenbach A., and Chung L. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147 (1992) 1151-1159
7. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol/Hematol 18 (1995) 51-64
8. Chiao J., Moonga B., Yang Y., et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83 (2000) 360-365
9. Achbarou A., Kaiser S., Tremblay G., et al. Urokinase overproduction results in increased skeletal metastasis by prostae cancer cells in vivo. Cancer Res 54 (1994) 2372-2377
10. Smith M., McGovern F., Zietman A., et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
11. Maillefert J., Sibilia J., Michel F., Saussine C., Javier R., and Tavemier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161 (1999) 1219-1222
12. Eriksson S., Eriksson A., Stege R., and Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and estrogens. Calcif Tissue Int 57 (1995) 97-99
13. Diamond T., Campbell J., Bryant C., and Lynch W. The effect of combined androgen blockade on bone tumover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83 (1998) 1561-1566
14. Shahinian V., Kuo Y., Freeman J., and Goodwin J. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
15. Smith M. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31 Suppl 3 (2005) 19-25
16. Tombal B., Rezazadeh A., Therasse P., et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 65 (2005) 178-187
17. Kumar R., Xiu Y., Yu J., et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 45 (2004) 2058-2062
18. Koga H., Naito S., Koto S., et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39 (1999) 1-7
19. Koizumi M., Yonese J., Fukui I., and Ogata E. The serum level of the aminoterminal propeptide of type 1 procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87 (2001) 348-351
20. de la Piedra C., Castro-Errecaborde N., Traba M., et al. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331 (2003) 45-53
21. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111 (2004) 783-791
22. Tamada T., Sone T., Tomomitsu T., et al. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19 (2001) 45-51
23. Eaton C., Wells J., Holen I., Croucher P., and Hamdy F. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59 (2004) 304-310
24. Hofbauer L., Neubauer A., and Heufelder A. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92 (2001) 460-470
25. Berruti A., Dogliotti L., Gorzegno G., et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45 (1999) 1240-1247
26. Berruti A., Dogliotti L., Bitossi R., et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164 (2000) 1248-1253
27. Brown J., Cook R., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59-69
28. Coleman R., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
29. Emrich L., Priore R., Murphy G., et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45 (1985) 5173-5179
30. Petrylak D., Scher H., Li Z., et al. Prognostic factors for survival in patients with hormone refractory bidimensionally measurable metastatic prostatic carcinoma treated with single agent chemotherapy. Cancer 70 (1992) 2870-2878
31. Kelly W., Scher H., Mazumdar M., et al. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 11 (1993) 607-615
32. Scher H., Kelly W., Zhang Z., et al. Post-therapy serum prostate specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91 (1999) 244-251
33. Smaletz o., Scher H., Small E., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
34. Halabi S., Small E., Kantoff P., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
35. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4 (2005) 31-37
36. Berruti A., Tucci M., Mosca A., et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 93 (2005) 633-638